Retour à la liste des essais cliniquesLung cancer

HARMONi-3

A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

Ouvert à Paris depuis le : 04/12/2024
Public cible : Adult
Phase : Phase III

Description de l'essai

To compare overall survival (OS) between ivonescimab combined with carboplatin and paclitaxel or nab-paclitaxel versus pembrolizumab combined with carboplatin and paclitaxel or nab-paclitaxel

Url of the trial

Investigateur principal

PAULINE DU RUSQUEC

Médecin

Contacter